New Drug Reviews

Selegiline Transdermal Patch (Emsam) for Major Depressive Disorder


Am Fam Physician. 2008 Feb 15;77(4):505-506.

Selegiline (Eldepryl) is an irreversible monoamine oxidase (MAO)-B inhibitor used at low doses for the adjunctive treatment of Parkinson's disease. The selegiline transdermal patch (Emsam) delivers higher, more sustained blood levels to the brain and is labeled for the treatment of major depression in adults.1,2

View/Print Table

NameStarting dosageDose formApproximate monthly cost*

Selegiline transdermal patch (Emsam)

Patch with a dose of 6 mg per 24 hours applied each day; may increase dosage by 3 mg per 24 hours at two-week intervals to a maximal dosage of 12 mg per 24 hours

Patches with a dose of 6, 9, or 12 mg per 24 hours


*— Average wholesale cost, based on Red Book, Montvale, N.J.: Medical Economics Data, 2007.

NameStarting dosageDose formApproximate monthly cost*

Selegiline transdermal patch (Emsam)

Patch with a dose of 6 mg per 24 hours applied each day; may increase dosage by 3 mg per 24 hours at two-week intervals to a maximal dosage of 12 mg per 24 hours

Patches with a dose of 6, 9, or 12 mg per 24 hours


*— Average wholesale cost, based on Red Book, Montvale, N.J.: Medical Economics Data, 2007.


Unlike oral MAO inhibitors, transdermal selegiline delivers antidepressant drug concentrations to the central nervous system without substantially impairing gastrointestinal MAO-A activity. At the target dose of 6 mg per 24 hours, tyramine dietary restrictions are not needed.2

Transdermal selegiline is contraindicated in patients taking selective serotonin reuptake inhibitors; dual serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; bupropion (Wellbutrin); mirtazapine (Remeron); buspirone (Buspar); and certain analgesics, vasoconstrictors, sympathomimetics, and anticonvulsants. Administration of these drugs with transdermal selegiline may cause serotonin syndrome or hypertensive crisis. After discontinuation of any of these agents (except fluoxetine [Prozac]), at least four to five half-lives of the drug or active metabolite (approximately one to two weeks) should elapse before initiating therapy with transdermal selegiline.2 At least five weeks should elapse between discontinuation of fluoxetine and beginning treatment with transdermal selegiline because of the long half-life of fluoxetine and its active metabolite. When switching from transdermal selegiline to another antidepressant or contraindicated drug, a washout period of two weeks is recommended.2

As with most other antidepressants, transdermal selegiline is not labeled for use in children. Its effectiveness in children has not been demonstrated, and there is an increased risk of suicidal thoughts and behaviors associated with antidepressants in this population.2 Transdermal selegiline is U.S. Food and Drug Administration pregnancy category C.2


Insomnia, dry mouth, dizziness, nervousness, and abnormal dreams occur in about 8 to 18 percent of patients on transdermal selegiline. In clinical trials, approximately twice as many patients on transdermal selegiline (7 percent) discontinued treatment because of adverse effects compared with patients taking placebo. Localized skin reactions will occur in about one third of patients and will result in 2 percent of patients discontinuing therapy. Skin reactions can be minimized by proper application of the patch; persistent reactions can be treated with local corticosteroids or oral antihistamines. Sexual dysfunction and orthostatic hypotension, which are common side effects of oral MAO inhibitors, are uncommon with transdermal selegiline.26


Transdermal selegiline is modestly effective in treating major depression. In clinical trials, approximately 33 to 40 percent of patients responded to treatment compared with 22 to 30 percent who took placebo; results in actual practice will likely be lower.36 Typical rates of response to other antidepressants are 70 percent in clinical trials and 30 percent in practice. Transdermal selegiline will prevent relapse over one year to a greater extent than placebo; however, one in six patients will still experience a relapse.6 Transdermal selegiline has not been directly compared with any other antidepressant.


A one-month supply of transdermal selegiline will cost approximately $493 for any strength. First-line antidepressants, such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine, paroxetine (Paxil), and sertraline (Zoloft), cost between $15 and $149 per month.


The starting and target dose of transdermal selegiline is an extended-release 6-mg/24-hour patch applied once daily. If necessary, the dosage may be increased by 3 mg per 24 hours at two-week intervals up to a maximal dosage of 12 mg per 24 hours.2

Patients should be informed that tyraminerich foods and beverages (e.g., aged cheeses; tap and nonpasteurized beers; nonfresh meat, fish, and poultry; concentrated yeast products; protein extracts) should be avoided during use and for two weeks after discontinuation of the 9-mg and 12-mg patches.2 The recommended dosage for patients 65 years or older is 6 mg per 24 hours.2

Bottom Line

Transdermal selegiline is an expensive treatment option for patients with major depressive disorder who have not responded to other antidepressants or who cannot swallow or take oral medications. Based on guidelines from the American Psychiatric Association, MAO inhibitor pharmacotherapy should be reserved for patients with atypical and treatment-resistant depression. Patient education is very important with this product because of potentially serious food and drug interactions.

Address correspondence to Sarah Melton, PharmD, BCPP, CGP, at Reprints are not available from the authors.

Author disclosure: Nothing to disclose.


show all references

1. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, Van-DenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007;47(10):1256–1267....

2. Emsam (selegiline transdermal system) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2007. Accessed November 12, 2007.

3. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869–1875.

4. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restriction in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208–214.

5. Feiger AD, Rickels K, Rynn MA, Zimbross DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354–1361.

6. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579–586.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series coordinator for AFP is Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Mass.



Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP


Oct 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article